On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

Title: On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

Volume: 8 Issue: 7

Author(s): Beni B. Wolf, Clifford Quan, Thuy Tran, Christian Wiesmann and Daniel Sutherlin

Affiliation:

Keywords: FAP, DPP4, dipeptidyl peptidase, prolyl peptidase, inhibitor, cancer

Abstract: Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.

Cite this article as:

Wolf B. Beni, Quan Clifford, Tran Thuy, Wiesmann Christian and Sutherlin Daniel, On The Edge of Validation – Cancer Protease Fibroblast Activation Protein, Mini-Reviews in Medicinal Chemistry 2008; 8(7) . https://dx.doi.org/10.2174/138955708784567449